Next Article in Journal
Transcriptome Analysis of Novosphingobium pentaromativorans US6-1 Reveals the Rsh Regulon and Potential Molecular Mechanisms of N-acyl-l-homoserine Lactone Accumulation
Next Article in Special Issue
A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation
Previous Article in Journal
Direct Cardiac Reprogramming: A Novel Approach for Heart Regeneration
Previous Article in Special Issue
Deacetylation of Histone H4 Accompanying Cardiomyogenesis is Weakened in HDAC1-Depleted ES Cells
Open AccessReview

Histone Deacetylase Inhibitors and Diabetic Kidney Disease

Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(9), 2630; https://doi.org/10.3390/ijms19092630
Received: 14 August 2018 / Revised: 29 August 2018 / Accepted: 31 August 2018 / Published: 5 September 2018
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease)
Despite recent clinical trial advances and improvements in clinical care, kidney disease due to diabetes remains the most common cause of chronic kidney failure worldwide. In the search for new treatments, recent attentions have turned to drug repurposing opportunities, including study of the histone deacetylase (HDAC) inhibitor class of agents. HDACs are a group of enzymes that remove functional acetyl groups from histone and non-histone proteins and they can affect cellular function through both epigenetic and non-epigenetic means. Over the past decade, several HDAC inhibitors have been adopted into clinical practice, primarily for the treatment of hematological malignancy, whereas other existing therapies (for instance valproate) have been found to have HDAC inhibitory effects. Here we review the current HDAC inhibitors in the clinic and under development; the literature evidence supporting the renoprotective effects of HDAC inhibitors in experimental diabetic kidney disease; and the adverse effect profiles that may prevent existing therapies from entering the clinic for this indication. Whereas recent research efforts have shed light on the fundamental actions of HDACs in the diabetic kidney, whether these efforts will translate into novel therapies for patients will require more specific and better-tolerated therapies. View Full-Text
Keywords: histone; epigenetics; kidney disease; diabetes; nephropathy; acetylation histone; epigenetics; kidney disease; diabetes; nephropathy; acetylation
Show Figures

Figure 1

MDPI and ACS Style

Hadden, M.J.; Advani, A. Histone Deacetylase Inhibitors and Diabetic Kidney Disease. Int. J. Mol. Sci. 2018, 19, 2630. https://doi.org/10.3390/ijms19092630

AMA Style

Hadden MJ, Advani A. Histone Deacetylase Inhibitors and Diabetic Kidney Disease. International Journal of Molecular Sciences. 2018; 19(9):2630. https://doi.org/10.3390/ijms19092630

Chicago/Turabian Style

Hadden, Mitchell J.; Advani, Andrew. 2018. "Histone Deacetylase Inhibitors and Diabetic Kidney Disease" Int. J. Mol. Sci. 19, no. 9: 2630. https://doi.org/10.3390/ijms19092630

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop